HomeCompareDBTX vs PG

DBTX vs PG: Dividend Comparison 2026

DBTX yields 40.73% · PG yields 2.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DBTX wins by $189.9K in total portfolio value
10 years
DBTX
DBTX
● Live price
40.73%
Share price
$4.91
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$241.3K
Annual income
$41,393.71
Full DBTX calculator →
PG
Procter & Gamble
● Live price
2.92%
Share price
$144.73
Annual div
$4.23
5Y div CAGR
31.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.4K
Annual income
$9,955.44
Full PG calculator →

Portfolio growth — DBTX vs PG

📍 DBTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDBTXPG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DBTX + PG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DBTX pays
PG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DBTX
Annual income on $10K today (after 15% tax)
$3,462.32/yr
After 10yr DRIP, annual income (after tax)
$35,184.65/yr
PG
Annual income on $10K today (after 15% tax)
$248.27/yr
After 10yr DRIP, annual income (after tax)
$8,462.12/yr
At 15% tax rate, DBTX beats the other by $26,722.53/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DBTX + PG for your $10,000?

DBTX: 50%PG: 50%
100% PG50/50100% DBTX
Portfolio after 10yr
$146.4K
Annual income
$25,674.57/yr
Blended yield
17.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PG right now

DBTX
Analyst Ratings
4
Buy
3
Hold
Consensus: Buy
Altman Z
-4.3
Piotroski
2/9
PG
Analyst Ratings
29
Buy
22
Hold
1
Sell
Consensus: Buy
Price Target
$167.67
+15.9% upside vs current
Range: $150.00 — $179.00
Altman Z
5.3
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DBTX buys
0
PG buys
0
No recent congressional trades found for DBTX or PG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDBTXPG
Forward yield40.73%2.92%
Annual dividend / share$2.00$4.23
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%31.1%
Portfolio after 10y$241.3K$51.4K
Annual income after 10y$41,393.71$9,955.44
Total dividends collected$182.5K$29.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: DBTX vs PG ($10,000, DRIP)

YearDBTX PortfolioDBTX Income/yrPG PortfolioPG Income/yrGap
1← crossover$14,773$4,073.32$11,003$382.92+$3.8KDBTX
2$21,431$5,623.97$12,205$520.11+$9.2KDBTX
3$30,556$7,624.86$13,674$712.22+$16.9KDBTX
4$42,856$10,160.16$15,507$985.02+$27.3KDBTX
5$59,173$13,317.44$17,847$1,378.96+$41.3KDBTX
6$80,500$17,185.12$20,913$1,959.19+$59.6KDBTX
7$107,985$21,849.55$25,044$2,834.00+$82.9KDBTX
8$142,936$27,392.04$30,786$4,189.46+$112.2KDBTX
9$186,827$33,885.90$39,052$6,357.54+$147.8KDBTX
10$241,299$41,393.71$51,429$9,955.44+$189.9KDBTX

DBTX vs PG: Complete Analysis 2026

DBTXStock

Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.

Full DBTX Calculator →

PGConsumer Staples

The Procter & Gamble Company provides branded consumer packaged goods worldwide. It operates through five segments: Beauty; Grooming; Health Care; Fabric & Home Care; and Baby, Feminine & Family Care. The Beauty segment offers conditioners, shampoos, styling aids, and treatments under the Head & Shoulders, Herbal Essences, Pantene, and Rejoice brands; and antiperspirants and deodorants, personal cleansing, and skin care products under the Olay, Old Spice, Safeguard, Secret, and SK-II brands. The Grooming segment provides shave care products and appliances under the Braun, Gillette, and Venus brand names. The Health Care segment offers toothbrushes, toothpastes, and other oral care products under the Crest and Oral-B brand names; and gastrointestinal, rapid diagnostics, respiratory, vitamins/minerals/supplements, pain relief, and other personal health care products under the Metamucil, Neurobion, Pepto-Bismol, and Vicks brands. The Fabric & Home Care segment provides fabric enhancers, laundry additives, and laundry detergents under the Ariel, Downy, Gain, and Tide brands; and air care, dish care, P&G professional, and surface care products under the Cascade, Dawn, Fairy, Febreze, Mr. Clean, and Swiffer brands. The Baby, Feminine & Family Care segment offers baby wipes, taped diapers, and pants under the Luvs and Pampers brands; adult incontinence and feminine care products under the Always, Always Discreet, and Tampax brands; and paper towels, tissues, and toilet papers under the Bounty, Charmin, and Puffs brands. The company sells its products primarily through mass merchandisers, e-commerce, grocery stores, membership club stores, drug stores, department stores, distributors, wholesalers, specialty beauty stores, high-frequency stores, pharmacies, electronics stores, and professional channels, as well as directly to consumers. The Procter & Gamble Company was founded in 1837 and is headquartered in Cincinnati, Ohio.

Full PG Calculator →
📬

Get this DBTX vs PG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DBTX vs SCHDDBTX vs JEPIDBTX vs ODBTX vs KODBTX vs MAINDBTX vs KMBDBTX vs CLDBTX vs CHD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.